Literature DB >> 30035857

Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information.

Katharina Kriegsmann1, Rémi Longuespée2, Michael Hundemer1, Christiane Zgorzelski2, Rita Casadonte3, Kristina Schwamborn4, Wilko Weichert4, Peter Schirmacher2, Alexander Harms2, Daniel Kazdal2, Jonas Leichsenring2, Albrecht Stenzinger2, Arne Warth2, Margaux Fresnais5,6, Jörg Kriegsmann3, Mark Kriegsmann2.   

Abstract

OBJECTIVE: Tissue slides analyzed by MS imaging (MSI) are stained by H&E (Haematoxylin and Eosin) to identify regions of interest. As it can be difficult to identify specific cells of interest by H&E alone, data analysis may be impaired. Immunohistochemistry (IHC) can highlight cells of interest but single or combined IHC on tissue sections analyzed by MSI have not been performed.
METHODS: We performed MSI on bone marrow biopsies from patients with multiple myeloma and stained different antibodies (CD38, CD138, MUM1, kappa- and lambda). A combination of CK5/6/TTF1 and Napsin-A/p40 is stained after MSI on adenocarcinoma and squamous cell carcinoma of the lung. Staining intensities of p40 after MSI and on a serial section are quantified on a tissue microarray (n = 44) by digital analysis.
RESULTS: Digital evaluation reveals weaker staining intensities after MSI as compared to serial sections. Staining quality and quantity after MSI enables to identify cells of interest. On the tissue microarray, one out of 44 tissue specimens shows no staining of p40 after MSI, but weak nuclear staining on a serial section.
CONCLUSION: We demonstrated that single and double IHC staining is feasible on tissue sections previously analyzed by MSI, with decreased staining intensities.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  MS; MS imaging; digital image analysis; immunohistochemistry; molecular pathology

Mesh:

Year:  2018        PMID: 30035857     DOI: 10.1002/prca.201800035

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  6 in total

1.  MALDI Mass Spectrometry Imaging for the Distinction of Adenocarcinomas of the Pancreas and Biliary Tree.

Authors:  Christine Bollwein; Juliana Pereira Lopes Gonҫalves; Kirsten Utpatel; Wilko Weichert; Kristina Schwamborn
Journal:  Molecules       Date:  2022-05-27       Impact factor: 4.927

Review 2.  Multimodal Imaging Mass Spectrometry: Next Generation Molecular Mapping in Biology and Medicine.

Authors:  Elizabeth K Neumann; Katerina V Djambazova; Richard M Caprioli; Jeffrey M Spraggins
Journal:  J Am Soc Mass Spectrom       Date:  2020-09-04       Impact factor: 3.262

3.  Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients.

Authors:  Eline Berghmans; Julie Jacobs; Christophe Deben; Christophe Hermans; Glenn Broeckx; Evelien Smits; Evelyne Maes; Jo Raskin; Patrick Pauwels; Geert Baggerman
Journal:  Cancers (Basel)       Date:  2020-04-02       Impact factor: 6.639

4.  De novo discovery of metabolic heterogeneity with immunophenotype-guided imaging mass spectrometry.

Authors:  Verena M Prade; Thomas Kunzke; Annette Feuchtinger; Maria Rohm; Birgit Luber; Florian Lordick; Achim Buck; Axel Walch
Journal:  Mol Metab       Date:  2020-02-14       Impact factor: 7.422

Review 5.  Mass Spectrometry Imaging Spatial Tissue Analysis toward Personalized Medicine.

Authors:  Juliana P L Gonçalves; Christine Bollwein; Kristina Schwamborn
Journal:  Life (Basel)       Date:  2022-07-12

Review 6.  Predictive Markers of Immunogenicity and Efficacy for Human Vaccines.

Authors:  Matthieu Van Tilbeurgh; Katia Lemdani; Anne-Sophie Beignon; Catherine Chapon; Nicolas Tchitchek; Lina Cheraitia; Ernesto Marcos Lopez; Quentin Pascal; Roger Le Grand; Pauline Maisonnasse; Caroline Manet
Journal:  Vaccines (Basel)       Date:  2021-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.